Navigation Links
Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
Date:11/12/2012

ayer Corporation, where he was responsible for the management of all biotechnology research activities within the Pharmaceutical Division. At Bayer, he managed five departments including molecular technologies, scientific informatics, cell and analytical biology, pharmacology and preclinical development. Prior to Bayer, he served in positions of increasing responsibility at Chiron Corporation. Dr. Zimmerman has been involved in the submission of dozens of Investigational New Drug applications to the U.S. Food & Drug Administration and other regulatory agencies in a variety of indications, as well as successful marketing applications including interleukin-2 (IL2) and beta-interferon.  Dr. Zimmerman received a doctor of science degree in physiology and radiobiology from the Harvard School of Public Health. He also earned a M.S. in physiology from The Ohio State University and a B.S. from Denison University.

"Dr. Zimmerman's extensive experience in drug development and his focus on risk mitigation will be extremely helpful as we begin to position MANF as a potential game-changing technology across a broad spectrum of applications related to apoptosis.  While Parkinson's remains our lead application, a comprehensive approach to advancing MANF towards the clinic may help us identify other opportunities that could substantially improve shareholder value in the near-term, without the deployment of significant additional resources," added Gerald E. Commissiong, President and CEO of Amarantus.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008.  The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases.  The Company owns the intellectual property rights to a therapeutic protein known as
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinsons Disease
3. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
4. Amarantus Biosciences and RBCC Outline Terms for NuroPro Parkinsons Blood Test Joint Venture
5. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
7. Neurocrine Biosciences Reports First Quarter 2012 Results
8. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
9. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
10. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
11. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... SINGAPORE , Sept. 15, 2014  Catalist-listed QT ... "the Group"), a developer and manufacturer of minimally invasive ... pleased to announce that the Group has enrolled the ... Germany . Multiple patients have already been ... , at Auckland City Hospital, in Auckland, ...
(Date:9/15/2014)... Sept. 15, 2014 PDL BioPharma, Inc. (PDL) (NASDAQ: ... paid the September 12, 2014, regular quarterly dividend payment of ... PDL as of September 5, 2014, the record date. ... manages a portfolio of patents and royalty assets, consisting ... and license agreements with various biotechnology and pharmaceutical companies. ...
(Date:9/15/2014)... , Sept. 15, 2014 Research and ... "Closed Drug Transfer Systems to 2020" report to ... deemed hazardous to humans has been receiving increasing amounts ... these substances become more clearly understood. For caregivers and ... forefront of attempts to mitigate exposure to cytotoxic drugs ...
Breaking Medicine Technology:First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5PDL BioPharma Completes Regular Quarterly Dividend Payment 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3
... Doubled Time to Progression and Overall Response Rate as ... in Patients with 2nd or 3rd Line Metastatic Colon ... KERX ) today announced data on the ... cancer, in combination with capecitabine as a treatment for ...
... increase the risk of breast cancer recurrence , ... found that taking tamoxifen with certain antidepressants more than ... taking both medications. The antidepressants inhibit an enzyme, CYP2D6, ... ) , , The study ...
Cached Medicine Technology:Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6New Research Shows Antidepressants May Thwart Breast Cancer Treatment 2New Research Shows Antidepressants May Thwart Breast Cancer Treatment 3
(Date:9/15/2014)... one out of every 40 individuals in the United States ... atrophy (SMA), a neurodegenerative disease that causes muscles to weaken ... made a recent breakthrough with the development of a new ... the disease. In April, a patent was filed for the ... is using to fight SMA is to ,repress the repressor," ...
(Date:9/15/2014)... September 15, 2014 In order to ... medicine often act conjointly to quantify, define and model ... become an integral part of medical care. , The ... the studies conducted by the non-profit Institute of BioAcoustic ... demonstrated that math can be much more than a ...
(Date:9/15/2014)... Dennis Thompson ... News) -- The severe respiratory virus believed to have ... states has now spread to the Northeast, health officials ... confirmed on Friday more than a dozen cases of ... for children with asthma. And on Saturday, the ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 As ... end of its first full year, there are ... maturing; especially in the evolution of its marketing ... approach being taken by Denver's Kindman, one of ... and distributors. , Kindman has pioneered the first-ever ...
(Date:9/15/2014)... September 15, 2014 As Risperdal lawsuits ... Bernstein Liebhard LLP notes that a new study has ... curbing aggression in children with ADHD when it is ... in behavioral management techniques. According to a report from ... and aggression problems, half of whom took Concerta, a ...
Breaking Medicine News(10 mins):Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 2Health News:Math as Medicine: The Promise of Frequency Domain BioMarkers as a Template to Predict, Enchance and Promote Optimal Health 3Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 2Health News:Kids' Severe Respiratory Virus Confirmed in Northeast 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4
... 2008) University of Minnesota researchers have created a beating ... called whole organ decellularization, scientists from the University of Minnesota ... dead rat and pig hearts and reseeding them with a ... in the January 13 issue of Nature Medicine., The ...
... injected into ,skeleton, of animal organ was beating in ... -- An organ-building biotechnology that could create transplantable hearts ... important laboratory tests, researchers report. , The technique, called ... heart tissue, according to a report in the Jan. ...
... here today," says James, a ClearChoices speaker. "I was,addicted ... I was at dinner each,night... they thought everything was ... and prevent them from going through what I went ... Chrysler LLC and,Barrett- Jackson will allow notMYkid to educate ...
... 500 Executive Driving Global Breast Cancer Leader,s Promise ... End Breast Cancer Forever, ATLANTA, Jan. 12 Hala ... the global leader in the fight to end breast,cancer forever, ... annual Trumpet Awards event in Atlanta with a ,High Heels ...
... LAUDERDALE, Fla., Jan. 11 eDiets.com,Inc. (Nasdaq: DIET ... Hamilton. Mr. Hamilton, who joined the Company in November,1999, ... privately held,company. Mr. Hamilton will remain available to assist ... firm to find a replacement and has,appointed Carla Cox, ...
... CHAPEL HILL, N.C., Jan. 11 Today,s top-level,pharmaceutical ... the,team that will carry out the plan as ... study by pharmaceutical research firm, Best,Practices, LLC., ... looking to invest people and money earlier in ...
Cached Medicine News:Health News:U of M researchers create beating heart in laboratory 2Health News:Biotechnology Builds a New Heart 2Health News:Biotechnology Builds a New Heart 3Health News:First in Nation: notMYkid Educational Center Is Now a Reality Thanks to a Partnership Between Chrysler, Barrett-Jackson and notMYkid 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 2Health News:Susan G. Komen for the Cure's CEO Hala Moddelmog Earns 'High Heels in High Places' Recognition at 2008 Trumpet Awards 3Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 2Health News:eDiets.com, Inc. Announces Resignation of Robert Hamilton, Chief Financial Officer 3Health News:Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes 2
... LactoSorb copolymer is an absorbable co-polymer ... acid and 18% glycolic acid. Unlike ... as 100% poly-L-lactic acid (PLLA) or ... is substantially amorphous (without crystallinity), meaning ...
... Tissue Anchor 2 mm is a resorbable repair ... using sutures. The resorbable repair device is implanted ... is used to reattach damaged soft tissue. The ... derived from glycolide and lactide colored with D&C ...
... of anchor is generally used when ... This 2.9mm anchor is packaged sterile ... or 2-0) and needles. Although pre-drilling ... the Mini Harpoon®, 1.6mm & 1.8mm ...
The MINI-TAG™ instrument systems are indicated for ulnar collateral ligament repair, scapholunate dissolution, flexor avulsions, and carpometa-carpal arthroplasty....
Medicine Products: